scispace - formally typeset
R

Richard Bucala

Researcher at Yale University

Publications -  622
Citations -  58697

Richard Bucala is an academic researcher from Yale University. The author has contributed to research in topics: Macrophage migration inhibitory factor & Cytokine. The author has an hindex of 119, co-authored 595 publications receiving 54607 citations. Previous affiliations of Richard Bucala include École Polytechnique Fédérale de Lausanne & Rockefeller University.

Papers
More filters
Journal ArticleDOI

Tumor growth-promoting properties of macrophage migration inhibitory factor.

Carlo Bifulco, +3 more
- 30 Nov 2008 - 
TL;DR: Macrophage migration inhibitor factor is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion.
Journal ArticleDOI

Autoimmune diseases: MIF as a therapeutic target.

Dorothee Greven, +2 more
- 12 Feb 2010 - 
TL;DR: In this article, a review of MIF-directed therapies as a novel therapeutic approach is presented, which covers literature from the past 10 years and shows that MIF inhibition has been shown to be efficacious in many experimental and pre-clinical studies of autoimmune inflammatory diseases.
Journal ArticleDOI

Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.

Xystus H. L. Tam, +5 more
- 01 Jan 2011 - 
TL;DR: Despite an increase in full-length RAGE expression, esRAGE expression was down-regulated in the diabetic patients, and serum sRAGE and esRAge was also reduced, Hence increased full- lengths RAGE levels are not associated with a similar increase in sRAge isoforms levels.
Journal ArticleDOI

Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention.

Wan-Uk Kim, +2 more
- 01 Jan 2009 - 
TL;DR: Pharmacologic modulation of TLR-directed pathways may offer new therapeutic approaches for the treatment of SLE.
Journal ArticleDOI

Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.

Sucheta Telang, +6 more
- 16 May 2012 - 
TL;DR: In conclusion, inhibition of the PFKFB3 kinase activity attenuates the activation of T cells in vitro and suppresses T cell dependent immunity in vivo and indicates that small molecule antagonists of PFK FB3 may prove effective as T cell immunosuppressive agents.